但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
All our favorite gear
。关于这个话题，搜狗输入法2026提供了深入分析
Мощный удар Израиля по Ирану попал на видео09:41
"It won't happen in two years, but we might be talking about 10 years for this to happen, and that's still a short period of time," he says.